Patients with Benign Prostatic Hyperplasia: Proportional representation of treatment procedures

Czech version

Authors: M. Louda ¹; E. Němečková ²; M. Broďák ¹; J. Košina ¹; J. Pacovsky ¹; L. Holub ¹; L. Rýdel ¹; P. Kutílek ¹; VL. Giblo ¹; P. Hušek ¹
Authors‘ workplace: Urologická klinika, FN a LF UK v Hradci Králové Přednosta: MUDr. Miloš Broďák, Ph. D. ¹; Farmaceutická fakulta UK v Hradci Králové Katedra biologických věd Vedoucí: doc. RNDr. Vladimír Semecký, CSc. ²
Published in: Prakt. Lék. 2010; 90(11): 670-671
Category: Of different specialties

Overview

We monitored the management of treatment for benign prostatic hyperplasia (BPH) in the urological department of Charles University hospital Medical faculty in Hradec Králové. The results comprise the number of surgical procedures of BPH including

– endoscopic – transurethral resection of prostate (TURP),

– open surgery – transvesical prostatectomy (TVPE), and the

– number of patients treated by pharmacological therapy.

All cases from the year 2003 to 2007. All methods were compared.

The most common surgical procedure was TURP. We noted a decreasing tendency in the number of performed TURP to the number of all patients treated for BPH. Last year the rate of TURP was only 5.47 % of all patients treated for BPH. TVPE was performed in approximately 0.8 % of cases. Pharmacological treatment was preferred before surgical procedures.

Key words:
benign prostatic hyperplasia, transurethral resection of prostate, transvesical prostatectomy.

Sources

1. Broďák, M., Holub, L. Farmakoterapie benigní hyperplazie prostaty – prevence, účinné preparáty, nežádoucí účinky. Urolog. pro Praxi 2006, 5, s. 210-213.

2. Poršová, M., Kolombo, I., Porš, J. a kol. Farmakoterapie benigní hyperplazie prostaty. Urolog. pro Praxi 2008, 9, s. 223-229.

3. Kim, C.I., Chang, H.S., Kim, B.K. Park, C.H. Long-term results of medical treatment in benign prostatic hyperplasia. Urology 2006, 68(5), p. 1015-1019.

4. Zámečník, L., Novák, K., Dvořáček, J. Současné trendy v léčbě benigní hyperplazie prostaty. Urolog. pro Praxi 2004, 6, s. 95-96.

5. Kolombo, I., Porš, J., Poršová, M. a kol. Benigní hyperplazie prostaty-BPH. Urolog. pro Praxi 2008, 9, s. 138-142.

6. Klečka, J., Hora, M. Benigní hyperplazie prostaty a současné trendy v léčbě. Urolog. pro Praxi 2007, 3, s. 120-126.

7. De la Rosette, J., Alivizatos, G., Madersbacher, S. et al. EAU guidelines on benign prostatic hyperplasia. European Association of Urology, 2006 [on-line]. Dostupné z www.uroweb.org/fileadmin/user_ upload/Guidelines/11%20BPH.pdf.

8. Lepor, H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev. Urol. 2004, 6, p. 3-10.

9. Parsons, J.K., Bergstrom, J., Silberstein, J. et al. Prevalence and characteristics of LUTS in men aged ≥80 years. Urology. 2008, 72, p. 318-321.

Labels

General practitioner for children and adolescents General practitioner for adults

Evolution and evolutionary theory for physicians. Evolution of human language

Testosterone and lifestyle diseases

Antiaggregation and gastroprotective drugs

Trace elements and bone

Current understanding of rhinosinusitis or familiarization with the European consensus on rhinosinusitis and nasal polyposis (EP3OS)

Treatment of hypertensive patients in ambulatory care in Slovakia

Advance directives of patients and perception of this problem in the Czech republic and Germany

Alcohol, tobacco, drugs and reproductive risks

Bronchial asthma and allergic rhinitis in employees in the manufacture of homemade dumplings

Article was published in

General Practitioner

2010 Issue 11